At-Home Sperm Testing Market
Legacy, Dadi, YO, ExSeed, SpermCheck, Fellow
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Some devices FDA 510(k)-cleared (YO, SpermCheck); mail-in lab services use CLIA labs
Reference only. Not medical advice.
What can go wrong
A normal screening result can falsely reassure: most home devices do not assess morphology, pH, or DNA fragmentation, and a single sample cannot rule out male-factor infertility. SpermCheck Fertility reports only whether concentration is above or below roughly 20 million/mL, not motility. Sample degradation in transit and user error can skew results. An abnormal result warrants a clinician-ordered WHO-standard analysis.
This is something to take to a clinician. The Atlas can tell you what is known about at-home sperm testing market in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
A consumer market splitting into two models: smartphone/lateral-flow devices that test at home (YO, SpermCheck, ExSeed, SwimCount) and mail-in kits analyzed at CLIA labs (Legacy, Dadi, Fellow). What each measures varies widely, and several pair testing with a sperm-cryopreservation subscription marketed as fertility insurance. None substitutes for a physician-ordered evaluation when results are abnormal.
Direct-to-consumer semen analysis, and a freezing-as-insurance upsell.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Smartphone devices (YO) clip an optical module to a phone and use the camera plus an app to estimate motile sperm concentration from a live video; lateral-flow tests (SpermCheck) use a chromatographic immunoassay against the sperm acrosomal protein SP10 to flag a concentration threshold. Mail-in services (Legacy, Dadi, Fellow) ship a sample in protective transport media to a CLIA-certified andrology lab for a technician-read analysis.
What the brands measure, and what they skip
ExSeed (per the manufacturer) reports volume, concentration, motility, and total motile count but does not check morphology or pH. YO (per the manufacturer) reports concentration, motility, progressive motility, and motile/progressive-motile concentration with a recorded video. SpermCheck (per the manufacturer) is a simple concentration threshold flag. Legacy and Dadi run a fuller lab analysis but as a paid service. Marketers describe at-home testing as 'as reliable as in-clinic'; independent validation varies by device and the cited accuracy figures are manufacturer claims.
What people get wrong
Often saidA normal home test means I am fertile
ActuallyHome tests screen a limited set of parameters from one sample. Morphology, DNA fragmentation, hormonal causes, and obstruction are not assessed, and male fertility is not determined by concentration alone.
Often saidFreezing my sperm now guarantees a future baby
ActuallyCryopreservation preserves a sample but does not guarantee conception; outcomes still depend on sperm quality, the female partner, and assisted-reproduction success rates. The 'insurance' framing is marketing, not a clinical guarantee.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- How do device accuracy claims hold up in independent head-to-head validation against WHO-standard lab analysis?
- Does easy at-home testing improve outcomes, or mainly drive freezing upsells?
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Home devices generally run tens of dollars; mail-in analyses run from roughly $295 and bundles with freezing and multi-year storage exceed $1,000, with annual storage fees thereafter (per company-listed pricing).
At a glance
- YO accuracy claim
- Manufacturer states 97%
- SpermCheck accuracy claim
- Manufacturer states over 98%
- ExSeed accuracy claim
- Manufacturer states greater than 95%
- Legacy storage entry price
- Manufacturer lists from ~$245/year
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about At-Home Sperm Testing Market. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
YO Home Sperm Test FDA 510(k) clearance (K161493)2016
Cleared as an OTC device measuring motile sperm concentration; basis for the manufacturer 97% accuracy positioning
Simplified sperm testing devices review (PMC8051200)2021
Concluded simplified devices can expand access in low-resource settings but vary in measured parameters and validation
SpermCheck Vasectomy 510(k) (K073039)2008
Cleared as a qualitative test detecting sperm at or above ~250,000/mL